Mark A. Hallman, MD, PhD

Request an Appointment Online - Click Here New patients can request an appointment online or call
888-FOX-CHASE

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111

Video: Mark Hallman, MD, PhD

Mark Hallman, MD, PhD
Dr. Mark Hallman

Radiation Oncology

Radiation Oncologist
Assistant Professor

Meet other members of the
lymphoma, leukemia and myeloma treatment team;
the lung cancer treatment team;
the genitourinary cancer treatment team.

Clinical Expertise:

My primary role is as a member of the thoracic oncology program treating lung cancer, mesothelioma and cancers of the thymus.  I also treat genitourinary cancers including prostate cancer, bladder cancer, and testicular cancer.  In addition I treat lymphoma and leukemia as a member of the hematologic malignancy program.

I have had extensive training in several specialized radiation techniques:

  • Intensity Modulated Radiation Therapy (IMRT)
  • Stereotactic Body Radiation Therapy (SBRT)
  • Prostate Brachytherapy

Certifications:

American Board of Radiology,
Radiation Oncology

Medical Education

M.D., Ph.D. in Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, 2009

Residencies

Department of Radiation Oncology
Fox Chase Cancer Center, Philadelphia, PA, 2014

Research Interests

My research has focused on improving the safety and efficacy of delivering SBRT.  I will also focus on developing new ways to deliver radiation treatments to cancers that are otherwise untreatable with conventional therapies. These methods will use exciting new drug and radiation combinations to enhance the effects and targeting of radiation on tumor cells.

Publications

  • Effects of active and inactive phospholipase 02 011 sig11GI transductio11, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells.
    Knoepp SM, Chahal MS, Xie Y, Zhang Z, Brauner DJ, Hallman MA, Robinson SA, Han S, Imai M, Tomlinson S, Meier KE. Mal Pharma col, 2008 Sep;74(3):574-84.
  • Regulation af dedifferentiation and redifferentiation in renal proximal tubular cells by the epidermal growth factor receptor.
    Hallman MA, Zhuang S, Schnellmann RG.
    J Pharmacol Exp Ther, 2008 May;325(2):520-8.
  • RasGRP1 confers the phorbol ester-sensitive phenotype to EL4 lymphoma cells.
    Han S, Knoepp SM, Hallman MA, Meier KE, Mol Pharmacol. 2007 Jan;71(1):314-22.
  • Effect of antioxida11ts 011 para-aminophenol-induced toxicity in LLC-PKl cells.
    Hallman MA, Tcaho R, Tarloff JB.
    Toxicology,  2000 Dec 7;156(1):37-45. 

Book Chapters:

  • Prostate, In: Radiation Oncology - Imaging and Treatment 1st ed, Ed: Gaffney DK, Amirsys, 2013, Section 6, p 54-79
    Hallman MA and Buyyounouski MB
  • Dedifferentiation and Redifferentiation  in Epithelial Repair, In: Comprehensive Toxicology 2°' ed, Ed: McQueen CA, Elsevier, Oxford, 2010, p 151-167
    Hallman MA and Schnellmann RG.